ForumIAS announcing GS Foundation Program for UPSC CSE 2025-26 from 19 April. Click Here for more information.
ForumIAS Answer Writing Focus Group (AWFG) for Mains 2024 commencing from 24th June 2024. The Entrance Test for the program will be held on 28th April 2024 at 9 AM. To know more about the program visit: https://forumias.com/blog/awfg2024
Source: The post is based on the article “Indian researchers developing treatment for rare genetic disorder ‘Duchenne Muscular Dystrophy” published in The Hindu on 10th January 2023
What is the News?
Researchers in India are working on developing an affordable treatment for a rare and incurable genetic disorder called Duchenne Muscular Dystrophy with over 5 lakh cases in the country.
What is Duchenne Muscular Dystrophy?
Duchenne muscular dystrophy is a genetic disorder. The disorder is marked by progressive muscle degeneration and weakness due to alterations of a protein called “dystrophin” that helps keep muscle cells intact.
The condition is predominantly seen in boys, but in rare cases, it can also affect girls.
Symptoms: Muscle weakness is the principal symptom of DMD. It can begin as early as age 2 or 3, first affecting the proximal muscles (those close to the core of the body) and later affecting the distal limb muscles (those close to the extremities). The affected child might have difficulty jumping, running, and walking.
Treatment: Currently, there is no cure for DMD, but improvements in integrative treatment can slow down the disease progression and thereby, extend the life expectancy of DMD patients.
What are the researchers from India developing?
The current therapeutic options available to treat DMD are minimal and highly expensive treatment with costs shooting up to Rs 2-3 crore per child a year and are mostly imported from abroad, accelerating dosing costs and putting them out of reach for most families.
That is why researchers from India are working on an affordable therapeutics for DMD.
